Specify a stock or a cryptocurrency in the search bar to get a summary
Quantum Genomics SA
ALQGCQuantum Genomics Société Anonyme, a biopharmaceutical company, engages in the development of drugs to treat cardiovascular diseases. The company develops its drugs based on brain inhibition mechanism of Aminopeptidase A: BAPAI, a triple-action therapeutic platform primarily to treat high blood pressure and heart failure. It is developing firibastat, a treatment for high blood pressure, and in combination with others anti-hypertensive drugs. The company also is involved in the development of drugs for the treatment of high blood pressure as monotherapy and the prevention, as well as treatment of heart failure. Quantum Genomics Société Anonyme was incorporated in 2005 and is based in Paris, France. Address: 33 rue Marbeuf, Paris, France, 75008
Analytics
WallStreet Target Price
9.28 EURP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures ALQGC
Dividend Analytics ALQGC
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History ALQGC
Stock Valuation ALQGC
Financials ALQGC
Results | 2019 | Dynamics |